Disparities in treatment with direct-acting hepatitis C virus antivirals persist in adults co-infected with HIV and hepatitis C virus in US clinics, 2010-2018

This article was originally published here

Care of AIDS Patients STDS. 2021 Oct; 35 (10): 392-400. doi: 10.1089 / apc.2021.0087.

ABSTRACT

Co-infection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) carries a substantial risk of all-cause mortality and liver-related morbidity and mortality, but many people co- infected with HIV / HCV are still not treated for HCV. We explored the demographic, clinical and socio-demographic factors in participants of routine HIV care associated with the prescription of direct-acting antivirals (DAAs). The HIV Outpatient Study (HOPS) is an ongoing longitudinal cohort study of people with HIV treated at participating clinics since 1993. There are currently eight study sites in six US cities. We analyzed data from the medical records of HOPS participants diagnosed with HCV since June 2010. A sustained virologic response (SVR) has been documented with the first undetectable HCV viral load (VL). We assessed the factors associated with DAA prescribing by multivariate logistic regression and described the cumulative SVR rate. Of the 306 eligible participants, 131 (43%) were prescribed DAA therapy. Factors associated with a greater likelihood of being prescribed an DAA were older age, private health insurance, higher CD4 cell count, being a person who injects drugs, and receive care in publicly funded sites (p

PMID: 34623891 | DOI: 10.1089 / apc.2021.0087

Source link

About Bradley J. Bridges

Check Also

HIV Associated Lipodystrophy Syndrome Treatment Market Size, Trends 2021, Growth, Share, Trends and Forecast to 2028

New Jersey, United States, – Global HIV Associated Lipodystrophy Syndrome Treatment market comprises market share, …